Longevity
Falling cardiolipin levels drive age-related muscle changes in mice
By Life and Health Today Staff, . Life and Health Today.
Researchers studying why muscles weaken with age have identified a specific molecular culprit: declining levels of a lipid called cardiolipin, which gives the inner membrane of mitochondria its distinctive shape and helps them function. The findings, reported in a paper covered by Fight Aging, show in mice that losing cardiolipin is not merely a side effect of ageing muscle but appears to cause some of its defining changes.
Mitochondria are the structures inside cells that produce adenosine triphosphate, or ATP, the chemical that powers most cellular activity. They become less effective with age, generating less ATP and more inflammatory byproducts. That much has been established for years. What has been harder to pin down is which of the many things that go wrong inside ageing mitochondria matters most.
The new work focused on cardiolipin synthase 1, the gene responsible for making cardiolipin. The researchers engineered young mice to lack that gene specifically in muscle tissue, mimicking the drop in cardiolipin that normally happens with age. According to Fight Aging's account of the paper, those young mice developed a hallmark of ageing muscle: a shift away from fast-twitch glycolytic fibers, which rely on sugar for quick bursts of force, toward slow-twitch oxidative fibers, which burn oxygen more steadily. The same shift is seen in human ageing and in muscle diseases called myopathies.
The mechanism the researchers identified runs from the mitochondria to the cell nucleus. Reduced cardiolipin appears to trigger signalling through a nuclear receptor called estrogen-related receptor gamma, which then promotes a rerouting of glucose metabolism to shore up the cell's antioxidant defences. In plain terms, the cell appears to be compensating for damaged mitochondria by changing which type of muscle fiber it runs.
The more striking result came when the researchers restored cardiolipin synthase 1 expression in adult mice that had been engineered to lack it. According to Fight Aging, restoring the gene reestablished cardiolipin levels, began to reverse muscle atrophy, and fully rescued what the paper described as premature mortality in those animals.
That last finding is the one that demands the most caution. The mice in question were engineered to lack cardiolipin synthase 1 from the start, not aged mice whose cardiolipin had declined naturally over time. Fight Aging noted this directly, observing that one would want to see the restoration experiment repeated in aged mice before drawing firm conclusions. That experiment has not yet been reported.
No human trial has tested whether raising cardiolipin levels in older people improves muscle function or any other outcome. The paper describes human skeletal muscle data consistent with the mouse findings, but consistency is not the same as causation, and the human observations were not from a controlled experiment.
The broader context matters here too. Fight Aging noted that attempts to improve mitochondrial function in older people through drugs and supplements have so far struggled to outperform exercise, which suggests that the mechanisms targeted have either not been the most important ones or have not been sufficient on their own. Cardiolipin may prove to be a more central target, but that remains to be shown.
What this work establishes, in young engineered mice, is that cardiolipin loss can cause the kind of muscle remodelling associated with ageing, and that restoring it can reverse some of those changes. Whether the same holds in naturally aged animals, and eventually in people, is the open question. Anyone weighing whether this is relevant to their own health should discuss it with a clinician who knows their history; no intervention targeting cardiolipin is currently available outside a research setting.
Life & Health Today provides information for educational purposes only, not medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional.